Compare Figs Inc (FIGS) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Zoetis Inc — how do they compare? Figs Inc trades at $15.84 (market cap $2.49B), while Zoetis Inc trades at $74.22 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 12.1× Figs Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Figs Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 33 Days and Zoetis Inc for 70 Days on average.
| FIGS | ZTS | |
|---|---|---|
Market Cap | $2.49B | $30.20B |
Volume | 5,964,311 | 6,175,327 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $147.53 |
52-Week Low | $6.90 | $69.09 |
Typical Hold Time | 33 Days | 70 Days |
Enterprise Value | $2.25B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS stock trades at $15.78, up 12.23% over the past day, reflecting strong momentum. The technical outlook is bullish, supported by moving averages, while recent earnings beats and raised 2026 guidance highlight fundamental strength. Revenue growth accelerated to 28.8% in Q2 2026, with international sales surging 67%, and the company maintains a high gross margin of 68.91%.
The investment outlook is positive, with a consensus price target of $18.00 implying 14% upside. However, risks include a rich valuation (P/E of 45.39) and execution challenges in sustaining growth. Analyst sentiment is predominantly bullish, with 60% recommending buy, but investors should monitor margin pressures and competitive dynamics.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed earnings performance, having beaten estimates in Q2 2026 but missing in Q1. Despite recent headwinds in U.S. companion animal sales, the company maintains strong profitability with 71.67% gross margins and 27.69% net income margins. Analyst consensus remains positive with a $87.33 price target, though technical indicators suggest near-term pressure with support at $70-$71.
Zoetis presents a compelling value opportunity with attractive valuation multiples (P/E 11.92, EV/EBITDA 9.4) and robust fundamentals, though near-term risks include competitive pressures in pet medications and weakening U.S. veterinary clinic traffic. The company's international and livestock segments show resilience, supporting long-term growth potential despite current market skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
